Sugar stocks have been fired up lately on expectations that the industry is set to turn a corner. While the sector has seen many false dawns on reform hopes in the past, the changes we are seeing this time around could turn out to be the real deal.
Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?
There are certain characteristics which make evaluating banking and finance stocks different from others which produce goods and services. Money cannot be lent to someone unless there is an inflow by way of capital or debt. Since it is not practical to lend only from capital, borrowing (or leverage) is the sustaining food for this business. Naturally in using this leverage, there are good and bad apples.
Amara Raja Batteries Limited (ARBL) is the second largest storage battery manufacturer in India by revenue. The organised sector is a duopoly structure with two major players, ARBL and Exide Industries.
If there’s talk in the stock markets today, it’s devoted to the upcoming Zomato IPO, which aims to mop up Rs 9,375 crore. Unlike the crop of recent private equity investor backed companies doing IPOs, this isn’t primarily an offer for sale. Zomato gets a whopping Rs 9,000 crore to deploy into its business mainly through a fresh issue of shares. Only one investor, Info Edge, will offload a Rs 375 crore stake. At the upper end of the price band of Rs 72-76, the post-offer market cap of listed Zomato will be around Rs 60,000 crore.
In a bull market, when fancied sectors command premium valuations, IPOs in that space also come with a stiff asking price. We have seen this in the chemicals space. However, when a sector has been languishing for long and sees pick up only in pockets, will an IPO from such a sector leave money on the table? More specifically, will GR Infraprojects be one such offer? Read our take.
Mobility powered by electricity is fast becoming a reality. And one space that is expected to see accelerated adoption of electric vehicles is the basic commuter space, made up of 2- wheelers, particularly scooters. Scooters are mostly used for short commutes, their electric versions have a more affordable purchase price after FAME II (Faster Adoption and Manufacturing of EV) subsidy and they have lower running costs than petrol scooters. With almost 40 lakh scooters sold in India in a year, annual sales of 40,000 units for high-speed EV scooters look small. There is scope for faster adoption driven by basic commuting, e-commerce, and low speed mobility needs.
Last month, we reviewed a lesser-known a consolidation play in the commodity space play as a story fitting a ‘special situations’ theme. We now issue a ‘buy’ call on this stock and recommend accumulating the stock in phases, preferably adding on dips, if opportunities arise.
RITES Limited, is a public sector undertaking (PSU) specializing in consultancy work in the fields of transport, infrastructure and related technologies. Established under the aegis of Indian Railways, this Miniratna (Category I) Schedule A PSU, was established in 1974 and was listed in the stock exchanges in July 2018. The Ministry of Railways owns 72.02% of the shares in RITES Limited. Starting out as an infrastructure consultant, the company evolved itself to offer both consulting and turnkey execution of engineering projects, leasing services and exports for the Indian Railways.
India Pesticides is launching an IPO totalling to Rs 800 crore – with fresh issue of shares worth Rs 100 crore and an offer for sale worth Rs 700 crore by the promoter group. At the upper end of the price band of Rs 290-296 the post-issue market cap of the stock on listing would be Rs3,400 crore and the post-issue price earnings ratio would be 25 times. The offer closes on June 25. The proceeds from fresh issues are planned to be utilised towards working capital requirement and other corporate purposes.
Analysis beyond the P&L and the Balance Sheet is a must if we have to take a long term view of any company. I am not referring to fundamental or technical factors, but to more number work based on the published accounts. I am referring to the cash flow. My approach is different from what most textbooks would prescribe. Statutorily the accounts do carry something called the ‘funds flow’. That is not what I mean when I talk about ‘cash flow’. In the past, during a few of my presentations, I have taken up some analytical work on companies like Sintex, ABG Heavy Industries where a reconstruction of the cash flow showed that the story was vastly different from what the EPS and the PE numbers were telling. A solid cash flow analysis can tell us what the health of the business is and based on what current and likely future trends are, what would be the outcome.
KIMS Hospitals or Krishna Institute of Medical Sciences Hospital is a multi-speciality hospital chain with 9 centres, focused on the Andhra Pradesh-Telangana region. The KIMS Hospital IPO seeks to raise a sizeable Rs 2,143 crore (at the upper end of its price band of Rs 815-825). Of this, Rs 1943 crore is an offer for sale from PE investor General Atlantic, the promoters, and 44 other shareholders. The remaining will be used to pay off the already low borrowings and for general corporate purposes. Does the KIMS Hospital IPO make for a good long-term bet?